Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFalpha Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma

Trial Profile

Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFalpha Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2015

At a glance

  • Drugs L19 TNF fusion protein (Primary) ; Melphalan
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Philogen
  • Most Recent Events

    • 29 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top